NDC12: Revising the National Drug Code Format and Drug Label Barcode Requirements for the U.S. Market

Why the NDC format is changing

The National Drug Code is a foundational identifier in the U.S. healthcare system. It appears on drug labels, in FDA listing systems, pharmacy and hospital software, claims and reimbursement workflows, warehouse systems, and many supply chain and patient safety processes.

Historically, the NDC has been a 10-digit numeric code divided into three segments:

• Labeler code for the manufacturer, repackager, or distributor
• Product code for the specific strength, dosage form, and formulation
• Package code for the package size and type

Because the current code space has been used flexibly, three main 10-digit segment formats are in use: 4-4-2, 5-3-2, and 5-4-1. In every case, the order is Labeler, Product, and Package, but systems must recognize and interpret multiple layouts.

This is manageable, but it creates additional logic and special handling across databases, Electronic Health Record systems, Warehouse Management Systems, billing platforms, pharmacy systems, and other applications.

The primary driver for change is the exhaustion of labeler codes. As more products and labelers enter the U.S. market, the available labeler code space in the current 10-digit framework is becoming increasingly constrained.

What changes under the proposed NDC12 structure

Under the proposed rule, the NDC becomes a 12-digit code with a standard 6-4-2 structure:

• 6 digits: Labeler code
• 4 digits: Product code
• 2 digits: Package code

This proposed change would expand the available pool of labeler codes, eliminate the coexistence of multiple 10-digit segment formats, and simplify system validation because the structure becomes uniform.

Existing NDCs are expected to convert to NDC12 primarily through the use of leading zeros in the appropriate segments. This allows previously assigned products to be carried forward into the new structure while aligning with the 6-4-2 standard.

Barcode requirements and labeling impact

Drug labels are already subject to barcode requirements under 21 CFR 201.25. The proposed rule updates those requirements so that barcodes encode the new 12-digit NDC once the rule is effective and applicable transition periods are complete.

This affects compatibility across the medication use process, including:

• Hospital and clinical scanning systems
• Retail and specialty pharmacy workflows
• Wholesaler and distributor supply chain systems
• Manufacturer labeling, packaging, and serialization processes
• Downstream product verification and inventory processes

Machine-readable barcodes may use linear symbologies such as UPC or GS1-128, or 2D codes such as GS1 DataMatrix. As the industry continues to adopt 2D barcodes for serialization and DSCSA compliance, the relationship between NDC12 and GTIN becomes a critical design decision.

Why GTIN mapping becomes more complex

One of the most important technical considerations is the relationship between NDC and GS1 GTIN-14.

Historically, U.S. drug products have often relied on a direct mapping from NDC10 into GTIN-14. NDC12 changes that assumption because GTIN-14 cannot natively accommodate a full 12-digit NDC plus prefix and check digit in the same way.

This means GS1, manufacturers, repackagers, distributors, and technology providers may need to adopt new interoperability models. Organizations should not assume that current NDC-to-GTIN logic will continue to work without change.

Areas to review

• Current NDC10, NDC11, and GTIN mapping rules
• Product master data structures and field-length limitations
• Labeling artwork and barcode generation logic
• Serialization repository and Level 4 system configuration
• Warehouse scanning and verification workflows
• Partner-facing data exchange and integration requirements

Who will be affected by NDC12?

The proposed NDC12 format affects a broad range of stakeholders across the U.S. pharmaceutical and healthcare ecosystem.

What companies should do now

Although the actual go-live timing for NDC12 remains dependent on final regulatory action and transition planning, preparation should begin now. The scale of the change means organizations will benefit from early assessment rather than waiting for final deadlines.

1. Map where NDC appears across your organization

Identify every system, database, label template, interface, report, transaction, and workflow where NDC values are stored, displayed, parsed, scanned, or exchanged.

2. Review field lengths and validation logic

Systems designed around 10-digit or 11-digit NDC assumptions may reject, truncate, misread, or incorrectly format 12-digit values.

3. Assess NDC-to-GTIN dependencies

Document where GTINs are generated, mapped, stored, or derived from NDC values. Pay special attention to serialization, packaging, barcode creation, and partner-facing exchange.

4. Include labeling and artwork teams early

Barcode changes can affect artwork, packaging lines, label approval cycles, and print validation. These workstreams often require more lead time than expected.

5. Coordinate with trading partners

NDC12 readiness depends on more than internal systems. Manufacturers, distributors, pharmacies, providers, payers, and technology vendors will need aligned testing and transition plans.

6. Build a practical transition roadmap

The right plan should prioritize high-risk systems, regulated processes, partner dependencies, and barcode-related workflows before lower-risk reporting or display changes.

The path forward

NDC12 represents a major shift in how drug products are identified and encoded in the U.S. market. The proposed move to a standardized 12-digit format is intended to expand capacity and reduce fragmentation, but the operational impact will reach far beyond regulatory labeling teams.

For many organizations, the most important work will happen inside the systems and processes that depend on NDC values every day: master data, labeling, serialization, GTIN management, warehouse scanning, pharmacy workflows, billing, claims, reporting, and partner integrations.

The companies that prepare early will be better positioned to reduce disruption, validate changes in a controlled way, and support smoother alignment across trading partners.

SCW helps pharmaceutical and life sciences organizations navigate these types of complex regulatory, serialization, and digital supply chain transitions with practical strategy, system readiness support, and implementation guidance.